Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $85.00

by · The Markets Daily

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price increased by The Goldman Sachs Group from $50.00 to $85.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

A number of other research analysts have also recently issued reports on the stock. Chardan Capital raised their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright lifted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Finally, Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.89.

Get Our Latest Report on ARWR

Arrowhead Pharmaceuticals Trading Down 0.7%

Arrowhead Pharmaceuticals stock opened at $64.56 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The stock has a market cap of $8.77 billion, a PE ratio of -806.90 and a beta of 1.21. The stock has a 50-day moving average of $57.23 and a two-hundred day moving average of $36.49. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $76.76.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the sale, the director owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. This trade represents a 22.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the completion of the transaction, the insider owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. The trade was a 18.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 510,836 shares of company stock worth $33,603,060. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ARWR. Vanguard Group Inc. increased its stake in Arrowhead Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock valued at $553,077,000 after buying an additional 510,798 shares during the period. Avoro Capital Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after purchasing an additional 300,000 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after purchasing an additional 2,774,933 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 1.0% in the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after acquiring an additional 28,193 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.

Read More